Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 8 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Praxis Precision Medicines Inc. has 10 pending office actions in Biotechnology & Pharmaceuticals. The docket is distributed among 10 examiners and 8 art units, showing examiner diversity with some art-unit overlap.
JACKSON-TONGUE, LAKIA J is the busiest examiner, with 1 pending matter. No examiner dominates the docket, so portfolio management should emphasize application-specific response planning and consistent scientific support.
The difference between examiner and art-unit coverage suggests that related matters may share examination environments even when assigned to different examiners. Counsel can use that structure to coordinate technical positions while preserving examiner-specific arguments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (10%) |
| §102 only | 2 (20%) |
| §112 only | 2 (20%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 3 (30%) |
| No statute on record | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| VALENROD, YEVGENY | 1 | 72.5% | +25.1% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
| JARRELL, NOBLE E | 1 | 80.9% | +10.0% |
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
| HUTTER, GILLIAN A | 1 | 54.5% | +46.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556958 | KCNT1 INHIBITORS AND METHODS OF USE | JARRELL, NOBLE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19066412 | DYNAMIC CLAMPS AND METHODS OF USE THEREOF | JACKSON-TONGUE, LAKIA J | — |
| 18852579 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18852396 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A DIAZASPIROHEPTANE CORE AND METHODS OF USE THEREOF | RICCI, CRAIG D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19066412 | DYNAMIC CLAMPS AND METHODS OF USE THEREOF | JACKSON-TONGUE, LAKIA J | — |
| 18927451 | TREATMENT OF NEUROLOGICAL DISORDERS | VALENROD, YEVGENY | — |
| 18852579 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18852396 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A DIAZASPIROHEPTANE CORE AND METHODS OF USE THEREOF | RICCI, CRAIG D | — |
| 18834466 | METHODS OF TREATMENT USING T-TYPE CALCIUM CHANNEL MODULATORS | LEE, CHIHYI NMN | — |
| 18746428 | FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CHANDRAKUMAR, NIZAL S | — |
| 18556958 | KCNT1 INHIBITORS AND METHODS OF USE | JARRELL, NOBLE E | — |
| 18555222 | METHODS OF TREATMENT WITH NEUROACTIVE STEROIDS | CHONG, YONG SOO | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1625 | 2 |
| 1645 | 1 |
| 1626 | 1 |
| 1627 | 1 |
| 1611 | 1 |
| 1699 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19066412 | DYNAMIC CLAMPS AND METHODS OF USE THEREOF | JACKSON-TONGUE, LAKIA J | 1645 | §102§112 | Non-Final OA | — | Pending | Feb 28, 2025 |
| 18864098 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | JACKSON, SHAWQUIA | 1626 | §102 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18927451 | TREATMENT OF NEUROLOGICAL DISORDERS | VALENROD, YEVGENY | 1628 | §103Other | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18852579 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | WHITE, DAWANNA SHAR-DAY | 1627 | §102§103§112 | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18852396 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A DIAZASPIROHEPTANE CORE AND METHODS OF USE THEREOF | RICCI, CRAIG D | 1611 | §102§103 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18834466 | METHODS OF TREATMENT USING T-TYPE CALCIUM CHANNEL MODULATORS | LEE, CHIHYI NMN | 1628 | §103§112DP | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18746428 | FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | — | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18556958 | KCNT1 INHIBITORS AND METHODS OF USE | JARRELL, NOBLE E | 1699 | §112 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18555222 | METHODS OF TREATMENT WITH NEUROACTIVE STEROIDS | CHONG, YONG SOO | 1623 | §112 | Final Rejection | — | Pending | Oct 12, 2023 |
| 17607815 | KCNT1 INHIBITORS AND METHODS OF USE | HUTTER, GILLIAN A | 1625 | §102 | Final Rejection | — | Pending | Oct 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPraxis Precision Medicines Inc. has 10 pending office actions as of October 2026, spread across 8 art units and 10 examiners.
Lakia J Jackson-Tongue has the most, with 1 of Praxis Precision Medicines Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
